大博医疗(002901) - 2025 Q2 - 季度业绩预告

Expected Performance for the Current Period The company expects its 2025 first-half performance to show a year-on-year increase, with net profit attributable to shareholders projected to be between 230 million and 250 million yuan, representing a growth of 66.37% to 80.84%, and net profit after deducting non-recurring gains and losses estimated at 210 million to 230 million yuan, a growth of 72.23% to 88.63% Key Financial Performance Indicators | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | Profit: 230 million – 250 million yuan | Profit: 138.244 million yuan | | Year-on-Year Growth | 66.37% – 80.84% | - | | Net Profit After Deducting Non-Recurring Gains and Losses | Profit: 210 million – 230 million yuan | Profit: 121.9312 million yuan | | Year-on-Year Growth | 72.23% – 88.63% | - | | Basic Earnings Per Share | Profit: 0.5657 – 0.6148 yuan/share | Profit: 0.3339 yuan/share | Communication with Accounting Firm The company has pre-communicated with its accounting firm regarding the performance forecast, with no disagreements, though the forecast data represents preliminary internal estimates and remains unaudited - The performance forecast data for this period is a preliminary estimate by the company's finance department and has not been audited by an auditing firm[4] - The company has pre-communicated with its accounting firm regarding the performance forecast, and there are no disagreements between the parties concerning this forecast[4][5] Explanation of Performance Changes Performance growth is primarily attributed to the company's product lines entering a new growth normal after centralized procurement of consumables, supported by ongoing strategies in product innovation, technical services, and international expansion, with approximately 25 million yuan in equity-settled payments recognized during the reporting period - The primary driver of performance growth is the company's product lines entering a new growth normal after centralized procurement of consumables[6] - The company consistently adheres to strategies of product innovation, technical services, and international development, promoting stable and healthy business growth[6] - Equity-settled payment expenses of approximately 25 million yuan were recognized during the reporting period[6] Risk Warning The company advises investors that this performance forecast is a preliminary estimate by the finance department, and the final accurate financial data will be based on the officially disclosed 2025 semi-annual report, urging investors to make cautious decisions and be aware of investment risks - This performance forecast is a preliminary estimate by the company's finance department, and the specific financial data will be subject to the company's officially disclosed 2025 semi-annual report[7] - Investors are advised to make cautious decisions and be aware of investment risks[7]